Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.38 |
| ▸ | MAS1 | P04201 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614742 | 1.00 | GP6 (0.39) | GP6AGTR2MAS1AGTR1OPRM1 | |
| SCHEMBL7652319 | 0.93 | TP53 (0.38) | GP6MAS1OPRM1OPRK1 | |
| SCHEMBL7652327 | 0.93 | TP53 (0.38) | GP6MAS1OPRM1OPRK1 | |
| SCHEMBL6231353 | 0.88 | PTGDR2 (0.36) | GP6AGTR2MAS1AGTR1 | |
| SCHEMBL6231352 | 0.88 | PTGDR2 (0.36) | GP6AGTR2MAS1AGTR1 | |
| SCHEMBL7611021 | 0.84 | GP6 (0.58) | GP6AGTR2AGTR1 | |
| SCHEMBL7611012 | 0.84 | GP6 (0.58) | GP6AGTR2AGTR1 | |
| SCHEMBL7616580 | 0.83 | IDO1 (0.38) | AGTR2OPRM1OPRK1EDNRA | |
| SCHEMBL7610225 | 0.83 | IDO1 (0.38) | AGTR2OPRM1OPRK1EDNRA | |
| SCHEMBL7609835 | 0.83 | GP6 (0.42) | GP6AGTR2MAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486189-B2 | TREATMENT OR PROPHYLAXIS OF AN ILLNESS CAUSED BY AN ISCHEMIC CONDITION, OR FOR THE TREATMENT OF IMPAIRED RESPIRATORY DRIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-11-26 | — | — | US | disclosed |
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | KLEEMANN HEINZ-WERNER (DE) | 2002-04-18 | — | — | US | disclosed |
| US-6335451-B1 | ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | BAX, BCL2, TNNI3 | GP6 2434/4885AGTR2 1901/4885MAS1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.